Teva Pharmaceutical Industries Ltd. (NYSE:TEVA – Get Free Report) EVP Richard Daniell sold 25,000 shares of the stock in a transaction on Monday, November 9th. The shares were sold at an average price of $42.91, for a total value of $1,072,750.00. Following the completion of the transaction, the executive vice president directly owned 55,755 shares in the company, valued at approximately $2,392,447.05. This represents a 30.96% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Richard Daniell also recently made the following trade(s):
- On Wednesday, November 11th, Richard Daniell sold 20,003 shares of Teva Pharmaceutical Industries stock. The shares were sold at an average price of $42.80, for a total value of $856,128.40.
Teva Pharmaceutical Industries Price Performance
TEVA stock traded up $0.28 during mid-day trading on Thursday, hitting $43.52. 9,218,408 shares of the stock were exchanged, compared to its average volume of 6,859,138. The company has a debt-to-equity ratio of 1.59, a current ratio of 0.95 and a quick ratio of 0.74. The business has a fifty day moving average price of $39.88 and a 200 day moving average price of $34.96. Teva Pharmaceutical Industries Ltd. has a 12 month low of $24.01 and a 12 month high of $44.31. The stock has a market capitalization of $50.72 billion, a price-to-earnings ratio of 101.22, a PEG ratio of 3.97 and a beta of 0.97.
Analyst Upgrades and Downgrades
A number of research analysts have commented on the stock. UBS Group increased their price target on shares of Teva Pharmaceutical Industries from $42.00 to $48.00 and gave the company a “buy” rating in a research report on Friday, September 4th. Piper Sandler boosted their price objective on shares of Teva Pharmaceutical Industries from $44.00 to $56.00 and gave the stock an “overweight” rating in a report on Thursday. JPMorgan Chase & Co. upped their price objective on shares of Teva Pharmaceutical Industries from $40.00 to $50.00 and gave the company an “overweight” rating in a research note on Monday, October 12th. HC Wainwright assumed coverage on shares of Teva Pharmaceutical Industries in a research note on Monday, November 2nd. They issued a “buy” rating and a $52.00 price objective for the company. Finally, Zacks Research lowered shares of Teva Pharmaceutical Industries from a “hold” rating to a “strong sell” rating in a report on Tuesday, October 20th. Thirteen equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Teva Pharmaceutical Industries presently has a consensus rating of “Moderate Buy” and an average price target of $48.15.
View Our Latest Analysis on Teva Pharmaceutical Industries
Teva Pharmaceutical Industries News Roundup
Investors following TEVA have been watching these news items:
- Positive Sentiment: Piper Sandler raised its price target to $56 from $44 and upgraded Teva to “overweight,” implying about 28% upside from the cited $43.74 share price. Piper Sandler ratings
- Neutral Sentiment: HC Wainwright made mixed earnings-estimate revisions: it raised its FY2027 EPS forecast to $3.07 from $3.03, but lowered estimates for some individual quarters, including Q4 2026 and Q3 2027. Its overall rating remains “Buy” with a $52 target. Teva analyst information
- Negative Sentiment: Healthcare shares were weaker in Wednesday afternoon trading, with the NYSE Healthcare Index down 0.6%, creating a possible sector-level headwind for TEVA. Healthcare sector update
Hedge Funds Weigh In On Teva Pharmaceutical Industries
A number of hedge funds have recently modified their holdings of TEVA. First Trust Advisors LP raised its stake in shares of Teva Pharmaceutical Industries by 693.7% during the third quarter. First Trust Advisors LP now owns 84,589 shares of the company’s stock valued at $3,350,000 after acquiring an additional 73,932 shares during the last quarter. Advisors Asset Management Inc. bought a new stake in shares of Teva Pharmaceutical Industries in the third quarter worth about $1,175,000. Edmond DE Rothschild Holding S.A. purchased a new position in Teva Pharmaceutical Industries during the 3rd quarter valued at about $1,648,000. USS Investment Management Ltd purchased a new position in Teva Pharmaceutical Industries during the 3rd quarter valued at about $10,840,000. Finally, WealthTrust Axiom LLC bought a new position in Teva Pharmaceutical Industries during the 3rd quarter valued at approximately $279,000. Hedge funds and other institutional investors own 54.05% of the company’s stock.
About Teva Pharmaceutical Industries
Teva Pharmaceutical Industries is a global pharmaceutical company that develops, manufactures and markets generic medicines, specialty medicines and biosimilars. Its portfolio spans treatments for conditions including neurological disorders, respiratory diseases and cancer, alongside a broad range of generic medicines across therapeutic areas. Founded in Jerusalem in 1901, Teva has grown from a regional pharmaceutical business into an international company. It serves patients and healthcare providers in markets around the world, including North America, Europe and other regions.
Further Reading
- Five stocks we like better than Teva Pharmaceutical Industries
- Can NVIDIA Maintain Its Momentum Without Huang?
- Six Flags Lost $366 Million in Q3—Its Insiders Just Went Shopping
- What Went Wrong With Amprius Technologies’ Q3? Less Than You’d Think
- Midterm Fallout, NVIDIA Turmoil, Anthropic’s IPO: Is Broadcom a Steal?
Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.
